creat
mockposit
bronchoalveolar
lavag
bal
spike
aspergillu
niger
broth
aliquot
bal
contain
known
haemophilu
influenzaehuman
adenoviru
b
coinfect
supplementari
materi
aspergillu
speci
chosen
optim
benchmark
given
thick
polysaccharid
cell
wall
extrem
clinic
import
invas
mold
patient
popul
test
nucleic
acid
extract
condit
combin
mockposit
bal
either
directzol
lysi
buffer
dnarna
shield
zymo
follow
mechan
homogen
either
mm
mm
glass
bash
bead
omni
cycl
second
bash
hz
second
rest
ice
cycl
tissuerlys
ii
qiagen
sampl
homogen
dnarna
shield
also
underw
enzymat
mycolysi
either
mg
mg
proteinas
k
minut
zymo
mg
mg
mg
mg
yatalas
takara
bio
inc
minut
subsequ
sampl
underw
minut
centrifug
supernat
use
parallel
dnarna
extract
zymo
zrduet
dnarna
miniprep
kit
aspergillu
niger
nucleic
acid
yield
measur
use
orthogon
digit
droplet
polymeras
chain
reaction
pcr
assay
panaspergillu
primer
supplementari
materi
rna
dna
sequenc
librari
prepar
parallel
new
england
biolab
nebnext
ultraii
librari
prep
underw
nucleotid
pairedend
sequenc
illumina
hiseq
instrument
supplementari
materi
resultantfastq
file
process
use
previous
describ
pipelin
consist
sever
opensourc
compon
briefli
read
underw
iter
remov
host
lowqual
lowcomplex
lzw
compress
ratio
redund
sequenc
use
star
priceseqfilt
cdhitdup
remain
sequenc
align
nation
center
biotechnolog
inform
ncbi
nonredund
nucleotid
databas
use
gsnapl
assign
taxonom
id
microb
describ
potenti
pathogen
typic
nonpathogen
base
priori
literatur
review
supplementari
materi
assess
microbi
contamin
reagent
laboratori
environ
sequenc
control
sampl
contain
spikedin
hela
rna
supplementari
materi
preval
microb
respiratori
sampl
describ
use
criteria
abund
rel
microb
sampl
wherein
normal
sequenc
read
per
million
total
sequenc
read
rpm
abund
rel
microb
sampl
cohort
wherein
normal
sequenc
read
number
standard
deviat
mean
rpm
total
cohort
zscore
given
anticip
wide
array
respiratori
bacteria
pauciti
knowledg
regard
signific
lowlevel
virus
fungi
aim
maxim
specif
bacteri
pathogen
maxim
sensit
viral
fungal
pathogen
therefor
defin
microbi
outlier
zscore
rpm
bacteria
rpm
virusesfungi
simpson
divers
index
use
associ
loss
bacteri
divers
presenc
outlier
microb
supplementari
materi
respiratori
sampl
outlier
pathogen
identifi
clinic
test
sent
refer
laboratori
orthogon
confirmatori
test
supplementari
materi
test
optim
mng
assay
prospect
screen
approach
immunocompromis
patient
age
year
undergo
clinic
indic
lower
respiratori
sampl
septemb
april
univers
california
san
francisco
benioff
children
hospit
indiana
univers
riley
hospit
children
univers
minnesota
mason
children
hospit
patient
enrol
consent
respiratori
sampl
collect
clinic
purpos
excess
volum
separ
place
dri
ice
within
minut
origin
procedur
bank
process
supplementari
materi
studi
approv
site
institut
review
board
iter
optim
demonstr
mechan
homogen
bal
use
glass
bash
bead
cycl
dnarna
shield
without
mycolyt
enzym
yield
highest
quantiti
niger
nucleic
acid
supplementari
materi
supplementari
figur
extract
protocol
perform
similarli
appli
clinic
isol
fumigatu
supplementari
figur
sequenc
rna
depth
million
read
per
bal
protocol
improv
lower
limit
detect
llod
niger
approxim
colonyform
unit
cfu
preoptim
confid
interv
ci
vs
cfu
postoptim
ci
pair
test
p
supplementari
figur
howev
sequenc
simultan
extract
dna
depth
yield
inferior
niger
llod
cfu
ci
pair
test
p
figur
optim
chang
detect
h
influenza
human
adenoviru
b
test
p
p
respect
use
optim
protocol
describ
conduct
mng
clinic
sampl
obtain
patient
tabl
sequenc
result
summar
sequenc
qualiti
report
supplementari
tabl
raw
sequenc
file
avail
ncbi
dbgap
http
wwwncbinlmnihgovprojectsgapcgibinstudycgi
detail
patient
result
appendix
neg
control
demonstr
minim
environment
contamin
rpm
pathogen
bacteria
pathogen
fungi
virus
supplementari
tabl
vast
major
taxa
deriv
bacteri
align
present
low
abund
quantiti
similar
across
sampl
cohort
specif
bacteri
genera
identifi
rpm
within
standard
deviat
cohort
mean
zscore
figur
includ
potenti
pathogen
bacteri
genera
escherichia
klebsiella
pseudomona
staphylococcu
stenotrophomona
streptococcu
identifi
nearli
sampl
level
well
detect
neg
control
sampl
respect
convers
detect
bacteri
genera
met
outlier
criteria
outlier
includ
potenti
pathogen
bacteria
identifi
patient
sampl
corynebacterium
enterobact
enterococcu
escherichia
haemophilu
klebsiella
mycoplasma
pseudomona
staphylococcu
streptococcu
sampl
outlier
bacteri
pathogen
significantli
depress
alphadivers
bacteri
microbiom
median
interquartil
rang
iqr
vs
iqr
p
figur
rel
bacteri
align
fungal
align
significantli
less
preval
cohort
fungal
genera
quantifi
rpm
figur
evid
support
align
limit
rariti
read
fungal
genera
met
outlier
criteria
includ
potenti
pathogen
fungi
identifi
patient
sampl
alternaria
aspergillu
candida
cladosporium
cryptococcu
fusarium
pneumocysti
aspergillu
rna
level
detect
patient
sampl
posit
invas
pulmonari
aspergillosi
ipa
cultur
galactomannan
assay
figur
label
although
remain
cultur
neg
receiv
fungicid
fungistat
antiaspergillu
pharmacotherapi
within
hour
sampl
collect
suggest
empir
antifung
pharmacotherapi
significantli
confound
associ
aspergillu
rna
growth
cultur
aspergillu
rna
level
correl
growth
cultur
test
p
demonstr
weak
associ
bal
galactomannan
p
supplementari
figur
contrast
bacteria
fungi
significantli
larger
portion
rna
align
viral
genera
present
high
abund
met
outlier
criteria
figur
communic
respiratori
virus
abund
align
identifi
approxim
one
third
patient
sampl
includ
adenovirus
c
bocaviru
coronavirus
influenzavirus
c
parainfluenzaviru
rhinovirus
c
although
rhinovirus
met
outlier
criteria
addit
rhinovirus
abund
zscore
addit
patient
viral
coinfect
influenzac
adenovirusc
rhinovirusa
although
case
clinic
suspect
herpesviru
pneumon
epsteinbarr
viru
cytomegaloviru
identifi
low
abund
sampl
viral
genera
uncertain
unlik
pathogen
also
identifi
sampl
includ
papillomavirus
wu
ki
polyomavirus
torquetenovirus
sampl
respect
clinic
test
identifi
caus
pathogen
sampl
n
figur
concordantli
identifi
outlier
mng
contain
outlier
quantiti
rna
align
second
previous
undetect
potenti
copathogen
bocaviru
corynebacterium
influenzac
addit
identifi
mng
classifi
outlier
case
aspergillu
diagnos
galactomannan
case
rhinovirusa
anoth
differ
outlier
pathogen
identifi
mng
coronaviru
twice
coronaviru
clinic
test
identifi
pathogen
sampl
n
mng
abl
identifi
statist
outli
potenti
pathogen
case
includ
varieti
bacteria
ie
p
aeruginosa
e
cloaca
pneumonia
fungi
ie
c
glabrata
virus
ie
rhinovirusa
statist
approach
separ
commens
pathogen
inher
imperfect
therefor
undertook
orthogon
valid
independ
mean
verifi
result
organ
detect
mng
clinic
test
valid
commerci
avail
clinic
laboratori
improv
amend
clia
approv
assay
perform
aliquot
origin
unprocess
sampl
supplementari
materi
valid
test
concord
mng
except
amplicon
dna
sequenc
fail
identifi
c
glabrata
sampl
sampl
confirm
presenc
organ
separ
speciesspecif
reversetranscript
primer
set
follow
sanger
sequenc
data
demonstr
mng
significantli
greater
sensit
detect
potenti
pulmonari
pathogen
current
clinic
diagnost
mcnemar
p
studi
develop
optim
mng
assay
adequ
sensit
identifi
bacteria
fungi
rna
dna
virus
within
lower
respiratori
tract
immunocompromis
children
identifi
rich
molecular
portrait
pulmonari
microbiom
vulner
popul
compar
quantiti
microbi
nucleic
acid
microb
within
sampl
sampl
within
cohort
abl
identifi
outli
potenti
pathogen
approxim
half
clinic
neg
sampl
due
inher
challeng
sampl
lower
respiratori
tract
pulmonari
microbiom
one
origin
site
studi
human
microbiom
project
explor
lag
decad
behind
similar
analys
human
intestin
cutan
nasopharyng
microbiom
addit
studi
pulmonari
microbiom
children
necessarili
lack
healthi
match
control
due
inher
risk
anesthesia
bronchoscopi
studi
found
mani
potenti
pathogen
bacteria
pseudomona
streptococcu
ubiquit
henc
abund
need
contextu
cohortspecif
norm
exampl
sampl
detect
pseudomona
rna
sampl
pseudomona
rna
detect
standard
deviat
cohort
mean
normal
populationdepend
measur
common
pediatr
appear
well
suit
describ
aspect
pulmonari
microbiom
date
major
metagenom
sequenc
assay
target
amplicon
within
rrna
subunit
allow
detect
pulmonari
bacteria
fungi
virus
recent
unbias
mng
assay
allow
detect
bacteri
viral
nucleic
acid
lack
ideal
sensit
detect
filament
mold
although
european
aspergillu
pcr
initi
describ
ideal
methodolog
extract
fungal
nucleic
acid
blood
optim
extract
condit
respiratori
specimen
remain
less
well
defin
studi
confirm
need
aggress
mechan
homogen
stabil
media
order
detect
mold
aspergillu
simultan
preserv
detect
bacteria
virus
major
commerci
sequenc
assay
measur
dna
studi
add
literatur
demonstr
rna
sequenc
time
sensit
detect
fastidi
organ
specul
may
due
high
copi
number
particular
rna
templat
present
activ
organ
use
optim
mechan
homogen
aspergillu
rna
detect
sampl
neg
control
suggest
lung
immunocompromis
children
frequent
expos
low
level
potenti
viabl
aspergillu
organ
data
novel
pediatr
popul
congruou
surveil
data
neutropen
nonneutropen
adult
howev
sampl
origin
patient
suspect
ipa
patientspecif
factor
antifung
pretreat
immun
reconstitut
alloreact
inflamm
impair
mucociliari
clearanc
remain
crucial
determin
child
might
develop
ipa
studi
power
assess
perform
characterist
assay
ipa
panfung
aspergillusspecif
pcr
demonstr
sensit
specif
probableproven
ipa
combin
nucleic
acid
test
galactomannan
hasten
diagnosi
improv
clinic
outcom
popul
incorpor
immun
function
may
also
improv
discrimin
colon
invas
mycosi
importantli
nucleic
test
measur
aspergillu
yield
vari
among
speci
accord
life
stage
cell
wall
characterist
hydrophob
therefor
futur
clinic
mng
assay
need
benchmark
numer
aspergillu
speci
well
medic
relev
fungi
order
broadest
util
consist
emerg
data
pediatr
also
detect
herpesvirus
cmv
low
abund
among
mani
children
cohort
interestingli
number
typic
nonpathogen
virus
torquetenoviru
ki
polyomaviru
present
half
cohort
data
support
direct
pathogen
virus
lack
may
indic
immun
dysfunct
predict
numer
posttranspl
infecti
alloimmun
complic
futur
studi
aim
character
longitudin
chang
pulmonari
virom
immunocompromis
children
warrant
character
distribut
pulmonari
microb
within
cohort
identifi
statist
outli
potenti
pathogen
half
clinic
neg
sampl
newli
detect
cultiv
organ
isol
patient
pretreat
antimicrobi
highlight
import
cultureindepend
techniqu
addit
sever
newli
detect
virus
includ
clinic
multiplex
pcr
assay
human
coronaviru
human
bocaviru
influenzavirusc
studi
suggest
mani
idiopath
pulmonari
complic
may
associ
infect
one
quarter
sampl
concordantli
neg
pathogen
clinic
mng
test
emphas
ongo
signific
noninfecti
pulmonari
complic
popul
futur
clinic
valid
mng
may
demonstr
util
safe
exclud
infect
allow
amplifi
immunomodul
patient
predominantli
inflammatori
pulmonari
syndrom
studi
sever
strength
first
optim
extract
aspergillu
spp
rna
preserv
detect
bacteri
viral
nucleic
acid
second
propos
logic
analyt
framework
rank
organ
abund
within
sampl
rel
sampl
third
outlier
pathogen
identifi
mng
detect
clinic
subsequ
valid
orthogon
assay
fourth
provid
knowledg
first
evalu
pulmonari
microbiom
immunocompromis
children
studi
sever
limit
first
zscore
use
deemphas
commonli
abund
organ
ie
pneumonia
may
overvalu
uncommon
organ
less
abund
transcript
ie
cmv
addit
larger
studi
natur
strengthen
util
zscore
analys
second
relationship
microb
quantiti
sequenc
read
vari
across
organ
base
nucleic
acid
access
avail
annot
refer
genom
futur
clinic
applic
mng
assay
requir
valid
numer
clinic
relev
speci
third
sampl
abund
nucleic
acid
human
epitheli
cell
leukocyt
virus
sourc
may
reduc
detect
spars
fastidi
microb
final
mng
assay
identif
microbi
nucleic
acid
directli
confirm
presenc
viabl
live
organ
directli
implic
microb
contributor
pulmonari
diseas
exclud
less
abund
organ
potenti
contributor
pulmonari
diseas
futur
studi
need
determin
whether
prospect
use
mng
clinic
relev
time
frame
might
affect
patient
manag
improv
outcom
order
optim
patient
outcom
advoc
ongo
multidisciplinari
collabor
among
clinician
laboratori
scientist
bioinformatician
summari
present
optim
mng
assay
reveal
rich
bacteri
fungal
viral
pulmonari
microbiom
immunocompromis
children
identifi
potenti
pathogen
half
clinic
neg
sampl
advanc
organ
detect
offer
potenti
earli
implement
target
therapi
possibl
improv
clinic
outcom
immunocompromis
children
invit
scientif
clinic
commun
particip
ongo
multicent
collabor
clinic
trial
aim
refin
emerg
technolog
